Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 8, 2007, Pages 923-932

  Helin Salmivaara, Arja ^a   Saarelainen, Sami ^b   Grönroos, Juha M ^c,d   Vesalainen, Risto ^c   Klaukka, Timo ^e   Huupponen, Risto ^d,f,g  

^a Laakehoidon kehittamiskeskus   (Finland)

^b 4Pharma Ltd   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e SOCIAL INSURANCE INSTITUTION   (Finland)

^f Clinical Pharmacology   (Finland)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Case control study; COX 2 selective NSAIDs; NSAID; Upper gastrointestinal hemorrhage

Indexed keywords

ACECLOFENAC; ARTHROTEC; CELECOXIB; CLOPIDOGREL; DICLOFENAC; ETODOLAC; ETORICOXIB; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROTON PUMP INHIBITOR; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; TENOXICAM; TIAPROFENIC ACID; TOLFENAMIC ACID; TRAMADOL; VALDECOXIB; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; FEMALE; FINLAND; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RISK; UPPER GASTROINTESTINAL TRACT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 34447122624     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701192326     Document Type: Article

References (39)

1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;43:1520-8.
2. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:65-674.
3. Silverstein F, Faich G, Goldstein J, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000;284:1247-55.
4. Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? Br Med J 2002;324:1287-8.
5. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998;37:937-45.
6. Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998;37:946-51.
7. Henry D, Lim L-Y, Garcia Rodrigues L, Gutthann SP, Carson JL, Griffin M, et al. Variability in risk of gastrintestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 1996;312:1563-6.
8. Mamdani M, Rochon P, Juurlink D, Kopp A, Anderson GM, Naglie G, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygense-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. Br Med J 2002;325:624-7.
9. Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety 2004;27:411-20.
10. Norgard B, Pedersen L, Johnsen SP, Tarone RE, McLaughlin JK, Friis S, et al. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther 2004;19:817-25.
11. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br Med J 2005;331:1310-6.
12. Drug consumption statistics. National Agency for Medicines. Available at: http:/www.nam.fi/english/medicines/drug_consumption/index.html (accessed 10.05. 2006).
13. Helin-Salmivaara A, Klaukka T, Huupponen R. Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland. Eur J Clin Pharmacol 2003;59:477-82.
14. Finnish statistics on medicines 2004. Helsinki: the National Agency for Medicines and the Social Insurance Institution; 2005.
15. ATC/DDD system. WHO. Available at: http:/www.whocc.no/atcddd/ (accessed 30.08. 2005).
16. Hosmer DW, Lemeshow S Jr, editor. Applied logistic regression. Hoboken, N.J.: Wiley & Sons; 2000.
17. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
18. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 2004;33:1-6.
19. Barden J, Edwards JE, McQuay HJ, Moore RA. Single dose oral celecoxib for postoperative pain. Cochrane Database Syst Rev 2003;CD004233.
20. Collins SL, Moore RA, McQuay HJ, Wiffen PJ, Edwards JE. Single dose oral ibuprofen and diclofenac for postoperative pain. Cochrane Database Syst Rev 2000;CD001548.
21. Barden J, Edwards J, Moore RA, McQuay HJ. Single dose oral diclofenac for postoperative pain. Cochrane Database Syst Rev 2004;CD004768.
22. Gabriel S, Jaakkimainen L, Bombardier C. Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
23. Bollini P, Garcia Rogdiguez L, Gutthann S, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992;152:1289-95.
24. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
25. Ofman JJ, Badamgarav E, Henning JM, Morton SC, Berger ML, Roth EA, et al. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis. Am J Med 2004;116:835-42.
26. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal anti-inflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004;50:2433-40.
27. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by nonsteroidal anti-inflammatory drugs: systematic review. Br Med J 2004;329:948.
28. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;CD002296.
29. Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Tugwell P, et al. Rofecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2005;CD003685.
30. Garner SE, Fidan DD, Frankish RR, Maxwell LJ. Rofecoxib for osteoarthritis. Cochrane Database Syst Rev 2005;CD005115.
31. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644-65.
32. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-81.
33. Zimmermann KC, Sarbia M, Schror K, Weber AA. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 1998;54:536-40.
34. McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol 1999;94:1218-23.
35. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997;112:387-97.
36. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995;310:827-30.
37. MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D. Channeling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003;52:1265-70.
38. Huupponen R, Helin-Salmivaara A, Sairanen S, Klaukka T. Painkillers are used differently in Finland compared to other Nordic countries (in Finnish). Finn Med J 2001;56:1904-8.
39. Helin-Salmivaara A, Virtanen A, Vesalainen R, Grönroos JM, Idänpään-Heikkilä JE, Klaukka T, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006;27:1657-63.